Objective: The objective of this work was to evaluate the effi cacy, acceptability and safety of the vaginal estriol on symptoms in postmenopausal women with urogenital atrophy. Design: Prospective clinical study. Setting: Department of Obstetrics and Gynecology of the 1st Medical Faculty and General Faculty Hospital, Prague. Methods: We included in our study 68 postmenopausal women with proved urogenital symptoms of the atrophic genitourinary tract. We administration them two years vaginal estriol 0.5 mg daily, later 1-2 times a week and than detected subjective and objective changes in their low urinary tract and vagina. These women had a normal biochemistry, uterus, mammary and bone density. These parameters were evaluated before starting the treatment and after 3 and 6 month. The statistical signifi cance of the phenomen was evaluated by exact t-test. Results: Statistically signifi cant positive differences and remission were observed in all symptoms and recurrent infection of the atrophical urogenital tissues. The fi rst satisfaction was after 3th month and the best after 6th month of this therapy, and in the end of this study (24 month) it was the same. We recorded no difference in other monitored parameters (endometrium, biochemistry, mammography, densitometry, blood pressure, weight) and compliance was satisfactory (85% after 6 months). In the 6 month profi le of estriol we found a signifi cant decrease of the Kupperman index and the Menopause rating scale. Conclusion: Administration of vaginal estriol is an advisable choice for every postmenopausal woman with the genitourinary problems (urgency, pollakisuria, dysuria, nycturia, recurrent infection of the low urinary tract). It has very good clinical effects and minimum side effects.

        Key words: estriol, genitourinary atrophy, urgency